ClinicalTrials.gg
RecruitingNCT06647589Updated Sep 28, 2026

Acceptance and Commitment Therapy for Religious OCD

An interventional study of Acceptance and Commitment Therapy in Obsessive-Compulsive Disorder (OCD), sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Sep 28, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 299 studies in Obsessive-Compulsive Disorder with a site in United States — 59 open to participants now, 77 under way, 2 of them phase 3. Obsessive-Compulsive Disorder · United States.

Planned enrollment
203rd of 246
10 · median 40
Started
2025
with 16 others
No phase
144 of 299
34 open now
Primary completion
2027-03
later than 24 of 76 live
Registered
276th of 299
by date

Among the 299 studies in Obsessive-Compulsive Disorder with a site in United States, this one is the 203rd largest by planned enrollment of the 246 interventional ones that give a count, is one of 17 that started in 2025, is one of 144 with no phase, reaches primary completion later than 24 of the 76 other live ones, and was the 276th registered.

Obsessive-Compulsive Disorder

636 studies on the registry are indexed under Obsessive-Compulsive Disorder; 166 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Open to participants now

59 of the 299 studies in Obsessive-Compulsive Disorder with a site in United States are open now. Recruiting first, the newest first:

53 more — sign in →

All 59 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 119 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 81 (68%) stop at 75 or younger; 28 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 299 studies in Obsessive-Compulsive Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to examine the effects and feasibility of a specific form of psychotherapy, acceptance and commitment therapy (ACT), on religiously oriented obsessive and compulsive disorder (OCD).

03

Conditions studied

  • Obsessive-Compulsive Disorder (OCD)

Keywords

  • scrupulosity
  • religion
  • acceptance and commitment therapy
  • obsessive-compulsive disorder
  • OCD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old
  • Meet cutoff scores for scrupulosity

Exclusion criteria

Exclusion Criteria:

  • Presence of psychotic symptoms within six months of screening
  • Current suicidal/homicidal plan/intent and/or a suicide/homicide attempt within 6 months of screening
  • Non-suicidal self-injury within 6 months of screening
  • Narcotics use within 3 months of screening
  • Purging/restricting behavior within 3 months of screening.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Acceptance and Commitment Therapy

    Participants will receive twelve consecutive weeks of acceptance and commitment therapy

    Behavioral: Acceptance and Commitment Therapy

Interventions

  • BehavioralAcceptance and Commitment Therapy

    participants will then receive ACT-based individual therapy weekly for twelve weeks.

06

What researchers measure

Primary outcomes

  1. Scrupulosity Obsessions and Compulsions Scale

    The Scrupulosity Obsessions and Compulsions Scale (SOCS) is a 10-item scale that asks participants how often they experience religious OCD obsessions and compulsions. The questions are asked on a scale ranging from 0 (Very Rarely) to 5 (Very Often).

    Time frame: At baseline, 4 weeks, 8 weeks, and post-intervention (12 weeks)

  2. Experiential Avoidance Rating Scale

    The Experiential Avoidance Rating Scale (EARS) is a 6-item scale that asks participants how true statements about avoiding experiences are for them. The questions are asked on a scale ranging from 1 (Never True) to 5 (Very Often True).

    Time frame: At baseline, 4 weeks, 8 weeks, and post-intervention (12 weeks)

Secondary outcomes

  1. Centrality of Religiosity Scale - Interreligious 20

    The Centrality of Religiosity Scale - Interreligious 20 (CRSi-20) is a 20-item scale assessing religiosity across 5 dimensions (Intellect, Ideology, Public practice, Private practice, Experience). The questions are asked on scales ranging from Never to Several times a day, Never to Very often, and Not at all to Very much so.

    Time frame: Pre and post intervention which in general lasts 12 weeks

  2. Yale-Brown Obsessive and Compulsive Scale - Self Report

    The Yale-Brown Obsessive and Compulsive Scale (Y-BOCS) is a 12-item scale that asks participants whether they experience various OCD obsessions and compulsions. Participants are then asked how much time is spent on these obsessions and compulsions, whether they give in to the urge to perform compulsions, how strong the drive is to give in to compulsions, how they would feel if they were prevented from engaging in compulsions, and how much the compulsions and avoidance of compulsions interfere with their functioning.

    Time frame: Pre and post intervention which in general lasts 12 weeks

  3. Patient Health Questionnaire - 9

    The Patient Health Questionnaire (PHQ-9) is a 9-item scale that asks participants how often they have been bothered by aspects of depressive symptoms. The questions are asked on a scale ranging from 0 (Not at all) to 5 (Nearly every day).

    Time frame: Pre and post intervention which in general lasts 12 weeks

  4. Generalized Anxiety Disorder - 7

    The Generalized Anxiety Disorder Scale (GAD-7) is a 7-item scale that asks participants how often they have been bothered by statements capturing aspects of anxiety. The questions are asked on a scale ranging from 0 (Not at all) to 3 (Nearly every day).

    Time frame: Pre and post intervention which in general lasts 12 weeks

  5. The Intrinsic Spirituality Scale

    The Intrinsic Spirituality Scale is a 6-item scale that asks participants about aspects of their spirituality.

    Time frame: Pre and post intervention which in general lasts 12 weeks

  6. Psy-Flex

    The Psyflex questionnaire is a 6-item scale that measures aspects of psychological flexibility. The questions are asked on a scale ranging from very seldom to often.

    Time frame: Pre and post intervention which in general lasts 12 weeks

  7. Almost Perfect Scale - Revised

    The Almost Perfect Scale - Revised is a 23-item scale that asks participants their agreement on items capturing perfectionism. The questions are asked on a scale ranging from 1 (Strongly disagree) to 7 (Strongly agree).

    Time frame: Pre and post intervention which in general lasts 12 weeks

  8. The Alcohol Use Disorders Identification Test

    The Alcohol Use Disorders Identification Test (AUDIT) is a 10-item scale that asks participants about their alcohol consumption.

    Time frame: Pre and post intervention which in general lasts 12 weeks

  9. National Institute on Drug Abuse Screener

    National Institute on Drug Abuse Screener (NIDA) is a 1-item scale that asks participants how often they use a variety of substances. The questions are asked on a scale ranging from Never to Daily or Almost Daily.

    Time frame: Pre and post intervention which in general lasts 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Mar 2027, 19 months after the start.

Of 234 non-industry interventional studies with no phase under Obsessive-Compulsive Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 65. This study's planned 19 months is below that.

Counting every sponsor, half of 237 studies reached it within 43 months; a quarter within 22 and three quarters within 65.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Sep 2026 → Mar 2027 and completion Sep 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2024
First posted
Oct 18, 2024
StartActual
Jul 30, 2025
Primary completionEst.
Mar 1, 2027was Sep 2026
CompletionEst.
Mar 1, 2027was Sep 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 1, 2026→Mar 1, 2027
Sep 28, 2026
Study completion
Sep 1, 2026→Mar 1, 2027
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Primary completion Sep 1, 2026→Mar 1, 2027
    Study completion Sep 1, 2026→Mar 1, 2027
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06647589
Responsible party
David Johnson (Graduate Student, University of Alabama at Birmingham) — Principal investigator
First posted
Oct 18, 2024
Start date
Jul 30, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

David Johnson
Contact
dajohns4@uab.edu
8013891733
Nicholas Borgogna, PhD
Contact
borgogna@uab.edu
7579693677

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion